Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 - Wikidata - wikimedia - TriplyDB

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

http://www.wikidata.org/entity/Q28242697

about

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis FGF signaling inhibits the proliferation of human myeloma cells and reduces c-myc expression Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations Chromosome translocations in multiple myeloma C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias Pleiotropic features of syndromic craniosynostoses correlate with differential expression of fibroblast growth factor receptors 1 and 2 during human craniofacial development Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models RSK in tumorigenesis: connections to steroid signaling.Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells Controlling destiny through chemistry: small-molecule regulators of cell fate.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.Multiple myeloma--evolving concepts of biology and treatment.Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors

P2860

Q22254704-938D5A4E-9612-459A-A2EF-4F6A83F61D70 Q24291107-06BCC6F3-2CC0-4BB8-AFED-E672035D9EAC Q24313675-07A9512B-1D35-48E3-B737-B1DC6E1FE53A Q24322575-49A5919A-3C50-4EE7-9701-C3034A0FB1D5 Q24548250-592FF950-7653-4BE8-B196-1651BA41059A Q24644538-62CF969A-70E4-4EF2-9BC8-94FF2BE57FBB Q24672803-26E71BD7-9CE1-487B-A9EA-FACDDF2C7E04 Q24804513-AA9BF90A-BE4B-43EB-AB2E-6F2D10813D47 Q24805521-A6E6506A-4BF6-4335-B581-EFEF96497EAC Q26998955-6C6C44EF-C0FD-466B-AE90-8210F92B3D5B Q27647832-F95A9C50-350B-4392-B00B-C1A0996FF3CD Q27654979-55830D9E-EC96-4573-AC75-B1E4BAA63A31 Q27679792-729E5EBA-CB1B-404F-BFE4-8DE2AB44499D Q27851612-3EA85A8C-39AA-46E1-B76A-38E762F54ADA Q27851654-57513284-35D9-4C59-BAC4-3E600286D922 Q28079309-C8ECDFD9-E8B9-4358-8DF9-D623D69E3D84 Q28140191-E93CA97C-CED1-4D5A-99BA-9F0A08B5E67A Q28199347-3EAC2C20-2C36-4319-8CC1-816B24839E7C Q28235799-3F655545-D9AC-479D-93A8-0FF41524F1EE Q28252023-CC206A15-2452-4CF2-8C2B-3913F35E0B1B Q28294004-F48E184E-8253-4A03-854E-5DC7815B4979 Q28592322-1ECC27CB-21F6-475E-AFD8-A1496EB2E611 Q28609639-A5E7D330-C815-49AC-BBE6-FA4758059907 Q28678621-BC7DA9CC-EBE1-4AB6-89FA-3A90D782130E Q28678660-37EFA0A5-08BE-4EE2-93F6-189ECC19722E Q28729944-AC416C03-8F94-4302-A0F2-165221BF0E8C Q30433106-D5EC4F28-CCB3-4513-97D1-4911DAEB087A Q30478353-C8BBC04A-1C53-4C2F-BB5A-94407F570FB7 Q30982341-6EAD0849-67C9-45C7-9FB8-03C7CE556D6C Q33593482-480CB122-033F-4253-AF70-26F92975C74B Q33632244-57893C1D-E1DD-4831-96A3-D355538404B7 Q33633815-FA5AF0A3-72D5-43CE-9ADE-D41791E5F242 Q33697369-7B943CCD-EC79-4A09-92B7-3246EFD0FDB8 Q33922373-F89DF8A4-87C6-4D21-928D-7CA53D2A30EC Q33983634-7C10A8EB-1993-4E6C-8525-D6D82A524B2E Q34025829-D44C194F-80A1-4539-B4B8-3D67903B53FB Q34152192-961A151C-A718-4EE5-A3F4-286D8EE14A32 Q34241661-CE757E6A-3427-460D-81D7-DF09FE36FDBD Q34285329-6CF93AA6-B24F-44A4-A287-200217C72B40 Q34375736-2DBF2658-E155-4863-8413-5F98C6FB5937

P2860

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

http://www.wikidata.org/entity/Q28242697

description

1997 nî lūn-bûn

@nan

1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@ast

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@en

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@nl

type

label

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@ast

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@en

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@nl

prefLabel

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@ast

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@en

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@nl

P1433

Q28242697-37F13429-FB3B-4C81-BA25-A13C75AC80AB

P1476

Q28242697-46D3F3A1-50EA-4FD2-8EB1-C2B13F937E53

P2093

Q28242697-1F501D64-B1D8-4994-96BF-B0D98E0FA6B4

Q28242697-5F9D5F65-D127-484D-BB04-32F86EA54E73

Q28242697-8A9203E2-05EA-48B8-B6A8-508ECEE4611F

Q28242697-8AABCC59-BAFF-4B2E-AAD6-673305E5DB0E

Q28242697-9DB2CEE2-BF07-4D75-84E9-970232EF5A4D

Q28242697-ACABD536-940B-452A-97EC-B30C0C6DF11F

Q28242697-D0215AD1-6281-4B99-AF12-A08CAEE7AFEE

P2860

Q28242697-17092ABE-DDC5-41F1-B8FB-A47F02887511

Q28242697-1DEB895B-0C3C-42DF-9CE9-95AB75A85048

Q28242697-20260B29-ACFD-4526-8085-4AB998850A4B

Q28242697-2826CBCF-3A2B-44C5-AC89-EA2F8646F10F

Q28242697-40FAAA22-8340-4658-90B6-243AE939ABD0

Q28242697-5F106D2A-24EB-4F80-92E4-18EDA717C45A

Q28242697-6170C8BE-770B-47C9-B661-468CAF9ADAFD

Q28242697-669FECB5-2ADA-4790-A110-67BEEA1B5DF3

Q28242697-66EBDC20-6FF0-4FD9-95A7-58937124C8CB

Q28242697-73652C97-96DA-4D20-873C-0A2362219D96

P2888

Q28242697-C2CB44D9-045F-4E5B-B2DE-A701AD91AD03

P304

Q28242697-D78D6883-E930-48FD-8B76-76EE98528A63

P31

Q28242697-656FEB87-9432-466D-9AFB-745E40BE9702

P3181

Q28242697-8A827BBD-B07A-4BBC-AA3B-53776D3FADE5

P356

Q28242697-16DE3936-F061-4E7F-B218-019F8FE24246

P407

Q28242697-309B3662-9894-4852-B5D1-69C678C925A6

P433

Q28242697-C8C8603F-07A5-4348-9E08-6F8FE65AD57A

P478

Q28242697-F38B459E-4832-43BD-A892-640C7E889FA3

P577

Q28242697-B6FFE7CF-C923-4EDB-BF4D-3A9B519FF2D9

P6179

Q28242697-A838951D-84AA-4289-9FBC-7800935493C8

P698

Q28242697-7B1AA623-24F7-4E4A-A5A2-3D2B79189547

P932

Q28242697-1AAACDA6-EDC6-4AD9-A624-FEE81FD1C59C

P3181

P356

P1433

Nature Genetics

P1476

Frequent translocation t(4;14) ...... blast growth factor receptor 3

@en

P2093

E Nardini

http://www.w3.org/2001/XMLSchema#string

E Schröck

http://www.w3.org/2001/XMLSchema#string

L A Brents

http://www.w3.org/2001/XMLSchema#string

M Chesi

http://www.w3.org/2001/XMLSchema#string

P L Bergsagel

http://www.w3.org/2001/XMLSchema#string

T Ried

http://www.w3.org/2001/XMLSchema#string

W M Kuehl

http://www.w3.org/2001/XMLSchema#string

P2860

Multicolor Spectral Karyotyping of Human Chromosomes

Fibroblast growth factor receptor 3 is a negative regulator of bone growth

Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3

Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3

Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia

Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)

Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II

Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster.

Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

P2888

P304

260-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1807106

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NG0797-260

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

1997-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032481248

http://www.w3.org/2001/XMLSchema#string

P698

9207791

http://www.w3.org/2001/XMLSchema#string

P932

3901950

http://www.w3.org/2001/XMLSchema#string